GlassScriptPhysician profile
Alison Anna Platt
NPI 1134371131
$1,836.48
in general payments reported to CMS, 2019-2025
15 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.19 · 2022: $153 · 2023: $212 · 2024: $596 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.79 | 2022-2025 | |
| Ardelyx, INC. | $188.81 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $167.23 | 2025 | Iqirvo |
| Janssen Biotech, INC. | $156.06 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $139.79 | 2022-2025 | Eohilia, Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.20 | 2024-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $77.92 | 2024-2025 | |
| Pfizer INC. | $74.42 | 2024-2025 | |
| Celgene Corporation | $39.64 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $38.51 | 2025 | Rezdiffra |
| Lilly USA, LLC | $37.90 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.97 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $28.67 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $22.08 | 2022 | |
| Fresenius Kabi USA, LLC | $15.49 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Platt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.